SightGlass Vision revealing new data on Diffusion Optics Technology at ARVO 2024 meeting

Image Credit: AdobeStock/AlexisS/peopleimages.com

SightGlass Vision will be bringing new data from 4 studies on its Diffusion Optics Technology (DOT 0.2) spectacle lenses to the 2024 Association for Research in Vision and Ophthalmology (ARVO) meeting from May 5-9 in Seattle, Washington.¹ The myopia control intervention technology uses thousands of light scattering elements to mimic natural contrast onto the retina, which acts to slow myopia progression in children, according to a news release.

“Our scientific program at ARVO 2024 adds to the substantial evidence supporting the myopia control efficacy of Diffusion Optics Technology, as well as guiding eye care professionals on making more informed choices regarding spectacle lens interventions. We are enthusiastic about how DOT lenses have been received in multiple countries and remain excited by the prospect of reaching even more children around the world,” said Andrew Sedgwick, CEO of SightGlass Vision, in the release.

Of the studies SightGlass will be citing, the CATHAY 2 year, randomized, controlled clinical trial worked to expand the company’s CYPRESS trial. The trial assessed myopia progression 71 participants ages 6 to 13 across 5 sites in China at the trial’s 6 month mark. The trial measured cycloplegic spherical equivalent refraction (cSER) and axial length (AL) compared to the standard single vision spectacle lens control group, and found that myopia progression was substantially slowed, according to the release. AL increased from baseline by 0.19 mm (p <0.001) compared to -0.05 mm (p+0.04) among DOT lens wears. Additionally, cSER increased from baseline by -0.38D (p<0.0001) versus 0.01D (p_0.85) with the DOT group. Unadjusted mean differences in the changes from baseline were -0.23 mm and 0.39D for AL and cSER, respectively.¹

“The CATHAY interim results further validate the findings from our multi-year CYPRESS study, supporting the hypothesis that modulating retinal contrast can slow myopia progression in children from diverse populations,” said Debbie Laughton, BSc, PhD, director of medical affairs for SightGlass Vision and first author of the CATHAY study, in the release.

Additional studies to be cited include trials led by first authors Asiya Jabeen, Reena Rani, and Leon N. Davies. Jabeen and investigators found thatmacula choroidal thickening in children followed short-term DOT spectacle wear, similar or great to response from +3.00D spectacle lens use. This indicates that the 2-visit, prospective , randomized, subject-masked crossover study resulted in contrast reduction that faborably affected the uveal tract tissue.¹

Rani and authors found that DOT, Defocus Incorporated Multiple Segments (DIMS), and Highly Aspherical Lenslets (HAL) performed well against the single vision lens when assessing high- and low-contrast visual acuity. Of the 3 myopia management technologies, DOT was found to have the greatest effect on visual acuity in the peripheral treatment zone. Davis and authors also discovered similar findings on DOT, DIMS, and HAL when assessing dynamic vision on the same participants.¹

SightGlass’s DOT is currently available in several commercial markets, including China, the Netherlands and Israel, and is in preliminary market trials in other countries around the globe.¹

Reference:

1. SightGlass Vision shares latest Diffusion Optics Technology data at ARVO 2024, affirming myopia management performance. News release. May 2, 2024. Accessed May 2, 2024.